Data from an international retrospective analysis of the response to BRAF/MEK inhibition in 96 advanced melanoma patients with rare BRAF V600 (n = 58) and non-V600 mutations (n = 38) revealed an overall response in 45% of V600 mutated patients but only 18% of non-V600 patients [13••]. Here, MAP2K7 is linked to melanoma.